BTAI BioXcel Therapeutics, Inc.
Partial dataBioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immu…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain Teva Pharmaceutical Industries Limited (NYSE:TEVA) has agreed to serve as the stalking-horse bidder for substantially all of BioXcel Therapeutics, Inc. (NASDAQ:BTAI)’s assets in a transaction valued at up to $125 million. The deal is structured as an upfront payment of $57.5 million followed by up to an additional $67.5 million in conditional milestone payments. Teva will […] | ||
 Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity? Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) and certain affiliates through a court-supervised Chapter 11 auction. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is the parent of the bidder and guarantor of the milestone-payment obligations. The […] | ||
 Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid TEVA's latest bid for BioXcel assets could expand its neuroscience portfolio with Igalmi and a potential at-home agitation treatment. | ||
 Teva Pharmaceuticals to acquire BioXcel assets for up to $125m The transaction would see Teva obtain worldwide rights to Igalmi and the investigational BXCL501. | ||
 Teva Pharmaceuticals to acquire BioXcel assets for up to $125m The transaction would see Teva obtain worldwide rights to Igalmi and the investigational BXCL501. | ||
 What Is Teva Pharmaceutical Industries (TEVA) Gaining From This Bankruptcy Drug Deal? Teva Pharmaceutical Industries (NYSE:TEVA) agreed to acquire BioXcel Therapeutics' dexmedetomidine sublingual film for at-home treatment of agitation in schizophrenia and bipolar disorder through a bankruptcy asset sale process. The transaction is subject to approval by the bankruptcy court, potential competing bids, and standard closing conditions before Teva can assume full rights to the asset. The dexmedetomidine sublingual film is under FDA review for at-home use. This transaction is... | ||
Teva (TEVA) Stock Looks Below Fair Value While Earnings Sit Above Fair Value Teva Pharmaceutical Industries stock has delivered a very strong 284.4% gain over the past 5 years, yet current checks send mixed signals as the Discounted Cash Flow (DCF) estimate points to undervaluation while market based multiples screen the shares as expensive. Investors looking at Teva today see a stock with powerful recent momentum against a low overall value score that suggests it is not a straightforward bargain. A 284.4% return over 5 years highlights how much Teva has already... | ||
BioXcel Therapeutics Enters Asset Sale Agreement With Teva Pharmaceuticals BioXcel Therapeutics (BTAI) has entered into an agreement with Teva Pharmaceutical Industries (TEVA) | ||
 BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +3.92% and -46.47%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates BioMarin (BMRN) delivered earnings and revenue surprises of +25.00% and +7.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||